Published 8 days ago

China is an open goal for Novo Nordisk’s obesity drugFinancial Times

Summary by Financial Times

Danish maker of Wegovy has little competition in the country and massive demand that it can take advantage of

0 Articles

All

Left

Center

Right

South China Morning Post

China approves Wegovy weight-loss drug made by Danish firm Novo Nordisk

The number of overweight adults in China, the world’s second most populous country, is projected to reach 540 million by 2030, according to a mainland public health study.

8 days ago·Hong Kong

Read Full Article

CNBC

Novo Nordisk's Wegovy weight loss drug approved in China

Novo Nordisk said Tuesday that its Wegovy weight loss treatment has been approved in China for long-term weight management.

8 days ago·United States

Read Full Article

Benzinga

Novo Nordisk Surges Nearly 3% After Weight Loss Drug Wegovy Wins Approval in China - Novo Nordisk (NYSE:NVO)

Novo Nordisk‘s (NYSE:NVO) weight loss drug Wegovy has received approval in China, representing a notable achievement for the Danish pharmaceutical firm. In response to this announcement, the company’s U.S.-listed stock is experiencing a surge of over 2% in pre-market trading on Tuesday. What Happened: The Chinese National Medical Products Administration has given the green light to Novo Nordisk’s Wegovy for long-term weight management, reported …

8 days ago·New York, United States

Read Full Article

MarketWatch

Novo Nordisk gains approval to sell weight-loss drug Wegovy in China

Europe’s most valuable company said Chinese regulators have approved its marketing application to sell Wegovy as a long-term weight-loss treatment for patients with obesity.

8 days ago·United States

Read Full Article